Glaukos Corp
A California eye-care company making tiny implants and dropless treatments for glaucoma and other eye conditions, its signature iStent is a micro-sized device placed in the eye to lower pressure. Founded in 1998, it pioneered micro-invasive glaucoma surgery with the first human implant of its stent in 2001. The name comes from ancient Greek "glaukos," meaning gleaming or blue-gray—the same root as the word "glaucoma."
Granted 484.1K · Sold 275.0K
Granted 36.8K · Sold 10.3K
Granted 15.8K
Granted 42.5K · Sold 53.9K
Granted 1.2K
Granted 13.3K · Sold 15.0K
Granted 15.6K · Sold 15.0K
Granted 15.7K · Sold 15.0K
Granted 15.6K · Sold 15.0K
Granted 623
Granted 623 · Sold 1.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Burns Thomas WilliamCHAIRMAN & CEO, Director · 24 transactions | +11.1% | 1.77M | 484.1K | — | 275.0K |
| Navratil TomasCHIEF DEVELOPMENT OFFICER · 32 transactions | +9.6% | 88.3K | 36.8K | — | 10.3K |
| Hoffmeister David FDirector · 2 transactions | +22.5% | 85.8K | 15.8K | — | — |
| Gilliam Joseph EPRESIDENT & COO · 21 transactions | -33.4% | 72.4K | 42.5K | — | 53.9K |
| Foley Mark JDirector · 1 transaction | +2% | 58.4K | 1.2K | — | — |
| Thurman Alex R.SVP & CHIEF FINANCIAL OFFICER · 11 transactions | +6% | 53.7K | 13.3K | — | 15.0K |
| Weisner Aimee SDirector · 8 transactions | +1.3% | 50.3K | 15.6K | — | 15.0K |
| Stapley MarcDirector · 7 transactions | +32.4% | 48.6K | 15.7K | — | 15.0K |
| Kliman Gilbert HDirector · 7 transactions | +1.8% | 35.5K | 15.6K | — | 15.0K |
| Torres DeniceDirector · 1 transaction | +2.9% | 22.3K | 623 | — | — |
| Wen LeanaDirector · 2 transactions | -5.2% | 19.7K | 623 | — | 1.7K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -400.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.